Altium Capital Management LP Bellus Health Inc. Transaction History

Altium Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $1.97 Million - $2.64 Million	220,000 Added 24.12%	1,132,000 $12 Million
Q2 2022 Aug 15, 2022	SELL	$6.46 - $10.02 $3.48 Million - $5.39 Million	-538,006 Reduced 37.1%	912,000 $8.43 Million
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $1.78 Million - $2.81 Million	-338,783 Reduced 18.94%	1,450,006 $11.7 Million
Q2 2021 Aug 13, 2021	BUY	$3.11 - $4.61 $669,894 - $992,994	215,400 Added 13.69%	1,788,789 $5.56 Million
Q1 2021 May 06, 2021	SELL	$3.03 - $4.58 $330,712 - $499,888	-109,146 Reduced 6.49%	1,573,389 $6.04 Million
Q4 2020 Feb 16, 2021	BUY	$2.27 - $3.3 $3.82 Million - $5.55 Million	1,682,535 New	1,682,535 $5.15 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.